Oyster Therapeutics

Oyster Therapeutics (formerly Kesmalea Therapeutics) is a London-based biopharmaceutical company developing next-generation targeted protein degraders (TPD), initially focused on tau-driven neurodegenerative diseases such as Alzheimer's. Its proprietary SELFTAC platform uses a reversible linker to convert large bifunctional degraders into small, orally available molecules designed to penetrate the central nervous system, and its lead program is an oral, brain-penetrant tau degrader intended to selectively remove pathological tau while preserving healthy tau. Built on foundational work by medicinal chemist Harry Finch and led by CEO Rob Johnson, the company is advancing its lead program toward clinical development and collaborates with Massachusetts General Hospital on tau biology.

  • Biotechnology
  • Clinical Trials
  • Healthtech
  • Pharmaceuticals
  • Targeted Protein Degraders
  • Healthcare & Life Sciences

1

Round

1

Industry

5

Tags

Nov 10, 2026

Latest raise

Funding activity · 1 round

Raise timeline

  1. Nov 10, 2026

    $60M

    Series A

    Led by 4BIO Capital

    • Oxford Science Enterprises
    • 4BIO Capital
    • Eli Lilly and Company
    • Mission BioCapital
    • CE-Ventures
    • Syncona
    • Actium Group
    • TOHO Ventures
    • MGB Ventures

    Article coming soon.

Pricing

Research Oyster Therapeutics — then scale the playbook

Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.

Enterprise

Custom pricing for unlimited scale. Let's talk.

Contact sales

Growth plan

For individuals and small teams getting started with AI buyer intelligence.

$149

/month

Features

  • Access to core AI adoption signals
  • 3–5 curated slices per week
  • 30–60 companies / week
  • AI Adoption Score
  • Deal-ready insights (why + pitch angle)
  • Basic filters (recency, slice, score)
  • CSV export
Most popular

Pro plan

For outbound teams and agencies that need more coverage and faster signal cadence.

$249

/month

Features

  • Everything in Growth, plus:
  • Full access to all slices
  • 60–120 companies / week
  • Higher-frequency signal updates
  • Priority / early signals (before Growth)
  • Advanced filters (industry, size, use case)
  • Deeper company insights
  • Faster export + bulk workflows

Act on this raise

See if Oyster Therapeutics is moving on AI

Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.

© 2026 VeilStrat. All rights reserved.All systems operational